Difference between revisions of "Bevacizumab-bvzr (Zirabev)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex")
 
(2 intermediate revisions by 2 users not shown)
Line 5: Line 5:
 
<br>Extravasation: [[neutral]]
 
<br>Extravasation: [[neutral]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/avastin-bevacizumab-342257 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/drug/avastin-bevacizumab-342257 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
Line 34: Line 34:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*2019-06-28: Approved ''(Based on STELLA)''
+
*2019-06-28: Approved ''(Based on REFLECTIONS B7391003)''
  
 
==Also known as==
 
==Also known as==
−
*'''Code names:''' MB-02, PF-06439535
+
*'''Code names:''' PF-06439535
 
*'''Brand name:''' Zirabev
 
*'''Brand name:''' Zirabev
  

Latest revision as of 01:48, 29 June 2024

Note: this is a biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication.

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

History of changes in FDA indication

  • 2019-06-28: Approved (Based on REFLECTIONS B7391003)

Also known as

  • Code names: PF-06439535
  • Brand name: Zirabev
Retrieved from "https://hemonc.org/w/index.php?title=Bevacizumab-bvzr_(Zirabev)&oldid=87462"